CAR engineered T cell therapy has developed rapidly in recent years. Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, Creative Biolabs is proud to present a new generation dual-switch CAR with two-dimensional regulation system of CAR-T cell therapy for both hematological and solid tumor models. Learn more: orthogonal dual-switch CAR-T Cell
